A study of tautomerism in N, N-dialkyl-4(5)-bromoalkanecarboxamides*

A. V. Lozanova, A. V. Stepanov, and V. V. Veselovsky*

N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky prosp., 119991 Moscow, Russian Federation. Fax: +7 (499) 135 5328. E-mail: ves@ioc.ac.ru

N,N-Dialkyl-4-bromobutanamides exist in solution in tautomeric equilibrium with N,N-dialkyl-N-(tetrahydrofuran-2-ylidene)ammonium bromides, while related 4,5-dibromopentanamides show no similar interconversions with the corresponding iminium salts. A similar difference is observed when comparing the chemical behavior of their homologs, *viz.*, N,N-dialkyl-5-bromopentanamide and N,N-dialkyl-5,6-dibromohexanamide

Key words: *N*,*N*-dialkyl-4(5)-bromoalkanecarboxamides, *N*,*N*-dialkyl-*N*-(tetrahydrofuran-2-ylidene)ammonium bromides, *N*,*N*-dialkyl-*N*-(tetrahydropyran-2-ylidene)ammonium bromides, ring—chain tautomerism.

Earlier,¹ we have reported on ring—chain tautomerism of a novel type detected by ¹H NMR spectroscopy in solutions of *N*,*N*-dialkyl-4-halo- (1) and *N*,*N*-dialkyl-5haloalkanecarboxamides (2) undergoing reversible interconversions into *N*,*N*-dialkyl-*N*-(tetrahydrofuran-2ylidene)- (3) and *N*,*N*-dialkyl-*N*-(tetrahydropyran-2ylidene)ammonium halides (4), respectively (Scheme 1). These systems show predictable thermal effects and are sensitive to the solvent polarity. The ratios of the tautomers in equilibrium mixtures (X = Br) under different conditions are given under Scheme 1.

Scheme 1

Later,² we have found that N, N-dialkyl-N-(tetrahydrofuran-2-ylidene)ammonium bromides 5, which are related to salts 3, can be obtained by bromination of N, N-dialkylpent-4-enamides and their derivatives (6) (Scheme 2). Acyclic bromination products of the type 7, whose formation is possible under these conditions, were not detected. Moreover, a ¹H NMR study of the behavior of iminium salts 5 in solutions revealed no signs of their possible transformations into the corresponding acyclic isomers 7. Apparently, the observed pattern is due to (1) a substantial rate difference between an intramolecular interaction of the bromonium ion with the carbonyl group and an attack of the bromide anion and (2) the higher (than for unsubstituted salts 3) energy of activation of the nucleophilic ring opening in compounds 5 at the secondary carbon atom.



Published in Russian in Izvestiya Akademii Nauk. Seriya Khimicheskaya, No. 6, pp. 1211–1215, June, 2010.

1066-5285/10/5906-1237 © 2010 Springer Science+Business Media, Inc.

We found it interesting to attempt an independent synthesis of dibromo amide of the type 7 and study its tendency toward cyclization into the corresponding iminium salt. It turned out that (\pm) -N-(4,5-dibromopentanoyl)pyrrolidine (7a) can be obtained in a conventional way from known 4,5-dibromopentanoic acid 8 and is a sufficiently stable crystalline solid (Scheme 3). However, melting of dibromide 7a (~50 °C) resulted in its complete transformation into iminium salt 5a: the ¹H NMR spectrum of the melt is identical with that reported^{2b} for compound 5a. The ~30% conversion of dibromide 7a into salt 5a was achieved when its solution in CDCl₃ was heated at 50 °C for 2 h.

Scheme 3



In contrast to the aforesaid reaction of unsaturated dialkylamides $\mathbf{6}$ with bromine, bromination of their homolog 9 (prepared from unsaturated acid 10) gives a ~ 3 : 1 mixture of cyclic iminium salt 11 and vicinal dibromide 12 (Scheme 4). This reaction outcome probably results from an intramolecular attack (a) of the amide O atom on bromonium cation 13 and a competitive reaction (b) involving the bromide ion. The structure of iminium salt 11 was confirmed by its hydrolysis to known lactone 14, as well as by elemental analysis and spectroscopic studies. Like its homologs 5 and in contrast to (tetrahydropyran-2-ylidene)ammonium salts 4, salt 11 in solutions undergoes no transformation into the corresponding acyclic tautomer 12 (¹H NMR data). We also found that even prolonged heating of a solution of dibromide 12 (MeCN, 81–82 °C, 6 h) does not produce, in contrast to dibromo amide 7a, appreciable amounts of the corresponding iminium bromide **11** (¹H NMR data).

Similar results were obtained in bromination of unsaturated phenylsulfonyl derivative **15** prepared by alkylation of known sulfonyl amide **16** with 4-bromobutene (Scheme 5). Workup of the reaction mixture gave isomeric iminium salts **17a** and **17b** in a total yield of 60% (**17a/17b** = \sim 1.7 : 1) and a \sim 1 : 1* mixture of diastereomeric dibromides **18**.





Scheme 5



Compounds 17 were isolated in the individual state using selective extraction and crystallization. The structures of these products and a mixture of diastereomers 18 were confirmed by physicochemical and elemental analyses. In particular, the relative configurations of the substituents in stereoisomers 17 were determined by comparing the experimental coupling constants of the protons in the ¹H NMR spectrum with the calculated ones. The calculations were performed with the MestrJ program (www.mestrec.com); the thermodynamically preferable conformations of stereoisomers 17 were found using the Gaussian program.³ Characteristic were the coupling constants of the HC(3) and HC(6) protons, for which the experimental and calculated J values are in satisfactory

^{*} The plausible ratio of diastereomers **18** in the mixture, which cannot be separated by chromatography. In the ¹H NMR spectrum of the mixture, the signals for the identical protons of the isomers overlap completely.

agreement (Table 1). Based on the data obtained, we assigned the $3R^*, 6S^*$ - and $3R^*, 6R^*$ -configurations to isomers 17a and 17b, respectively. Interestingly, in contrast to iminium salt 11 containing no phenylsulfonyl substituent, compounds 17 in solution undergo irreversible ring opening leading to the corresponding linear dibromides 18. In this respect, major isomer 17a is much more stable (half-conversion time ~20 days, CDCl₃, 20 °C, ¹H NMR), while minor isomer 17b is transformed into compound 18 virtually completely within ~12 h (CDCl₃, 20 °C, ¹H NMR). This difference in chemical behavior between isomers 17 provides indirect evidence for their structural features, namely, the pseudo-equatorial arrangement of both substituents (at the C(3) and C(6) atoms) in the thermodynamically preferable conformation of the more stable isomer 17a. In the less stable isomer 17b, one substituent (SO_2Ph) is in the pseudoaxial position.



Thus, our study revealed a dramatic influence of the position of the halogen atom in N,N-dialkylbromoalkanamides on their tendency toward ring—chain tautomerism.

Experimental

Melting points were measured on a Kofler hot stage. IR spectra were recorded on a Specord M-80 instrument. ¹H and ¹³C NMR spectra were recorded on Bruker AC-200, Bruker AM-300, and Bruker Avance 600 spectrometers at 298 K with reference to the solvent signals (δ 7.27 and 77.0 (CDCl₃) and δ 1.94 and 1.24 (CD₃CN), respectively). Mass spectra (EI, 70 eV) were measured on a Finnigan MAT ITD-700 instrument; an ESI mass spectrum was recorded on a Finnigan MAT LCQ spectrometer (capillary potential 4530 V). A solution of a sample in methanol was infused through a syringe into the ionization chamber at a rate of 10 µL min⁻¹; mass spectra (MS) (scan range from *m/z* 100 to *m/z* 2000) and tandem mass spectra (MS/MS) were recorded in the positive ion mode (helium was used as a gas for

 Table 1. Experimental and calculated coupling constants
 of selected protons in stereoisomers 17

Com- pound	Assignment	δ	$J_{\rm exp}$	$J_{\rm calc}$
			Hz	
17a	HC(3)	5.33	2.4, 9.6	2.2, 7.8
	HC(6)	5.10	3.0, 11.3	2.2, 10.3
17b	HC(3)	5.8	5.0, 7.0	3.8, 5.2
	HC(6)	5.00	2.5, 12.0	2.7, 11.6

collisional activation). The interface capillary temperature was 213 °C, the main nitrogen flow was 19.4 conventional units, and the auxiliary nitrogen flow was 0.4 conventional units. The observation time of activation in MS/MS spectra was 30 ms. The activation energy was taken to be 40% of the relative maximum collision energy. Column chromatography was carried out on Siluca gel 60 (0.04–0.06 mm, Fluka); $R_{\rm f}$ values were measured on Silufol plates. Solvents, including light petroleum (b.p. 40–70 °C), were purified and dried according to standard procedures. Pyrrolidine, N,N-diisopropylamine, hex-5-enoic acid, and thionyl chloride were the Acros Organics chemicals. (\pm)-4,5-Dibromopentanoic acid (8),⁴ N,N-diisopropyl-2-phenylsulfonylacetamide (16),^{2b} and 4-bromobutene⁵ were prepared according to known procedures.

(±)-N-(4,5-Dibromopentanoyl)pyrrolidine (7a). A stirred mixture of acid 8 (2.07 g, 8 mmol), SOCl₂ (9.1 g, 76.5 mmol), and DMF (0.3 mL) was heated at 50 °C (Ar) for 3 h and concentrated *in vacuo* to give 4,5-dibromopentanoyl chloride with the following ¹H NMR spectrum (200.13 MHz), δ: 2.08 (dddd, 1 H, HC(3), J = 5.6 Hz, J = 8.1 Hz, J = 10.0 Hz, J = 15.2 Hz); 2.66(dddd, 1 H, H'C(3), J=2.9 Hz, J=6.9 Hz, J=9.9 Hz, J=15.2 Hz);3.19 (m, 2 H, HC(2)); 3.61 (dd, 1 H, HC(5), J = 10.0 Hz, J = 10.1 Hz); 3.89 (dd, 1 H, H^C(5), J = 4.1 Hz, J = 10.1 Hz); 4.20 (dddd, 1 H, HC(4), J = 2.9 Hz, J = 4.1 Hz, J = 10.0 Hz, J = 10.0 Hz). This crude acid chloride was dissolved in CH₂Cl₂ (15 mL); a solution of pyrrolidine (1.14 g, 16 mmol) in CH₂Cl₂ (7 mL) was added with stirring at $-10 \,^{\circ}$ C (Ar) for 10 min. The reaction mixture was stirred at -10 °C for 1 h and concentrated in vacuo. The product was extracted with MeOBut and the extract was concentrated in vacuo. The resulting crude amide 7a (1.9 g, 76%) was subjected to low-temperature (-20 °C) crystallization from light petroleum to give amide 7a as colorless crystals, m.p. 45-49 °C*. Found (%): C, 34.38; H, 4.82; Br, 51.16; N, 4.41. C₉H₁₅Br₂NO. Calculated (%): C, 34.53; H, 4.83; Br, 51.05; N, 4.47. IR (KBr, v/cm⁻¹): 644, 784, 872, 916, 988, 1036, 1164, 1192, 1224, 1256, 1340, 1364, 1444, 1632, 2868-3028. ¹H NMR (200.13 MHz), δ: 1.80-2.14 (m, 5 H, HC(3), 2 CH₂); 2.42–2.74 (m, 3 H, H⁻C(3), 2 HC(2)); 3.47 (m, 4 H, HCN); 3.65 (dd, 1 H, HC(5), J = 9.0 Hz, J == 10.4 Hz); 3.86 (dd, 1 H, H'C(5), J = 4.5 Hz, J = 10.4 Hz); 4.33 (dddd, 1 H, HC(4), J = 2.5 Hz, J = 4.5 Hz, J = 9.9 Hz, J = 9.9 Hz).

N,N-Dimethylhex-5-enamide (9). Thionyl chloride (11.9 g, 100 mmol) was added with stirring at 60 °C for 40 min to acid 10 (6.84 g, 60 mmol) and DMF (60 mg). The reaction mixture was stirred at 80–100 °C (Ar) for 5 h and concentrated *in vacuo*. The residue was distilled to give the corresponding acid chloride (6.92 g) with b.p. 53-55 °C (30 Torr), which was dissolved in THF (15 mL). The resulting solution was added at -10 °C (Ar) to a stirred solution of dimethylamine (6.75 g, 150.0 mmol) in THF (70 mL). The reaction mixture was stirred at 0 °C for 1 h, kept at 20 °C for an additional 15 h, and treated with water (30 mL). The organic layer was separated, washed with water and brine, dried over Na2SO4, and concentrated in vacuo. The residue was distilled to give amide 9 (6.77 g, 92%) with b.p. 53–55 °C (1.0 Torr). ¹H NMR (200.13 MHz), δ: 1.71 (m, 2 H, H₂C(3)); 2.08 (m, 2 H, H₂C(4)); 2.26 (m, 2 H, H₂C(2)); 2.91 and 2.97 (both s, 3 H each, 2 Me); 4.89-5.06 (m, 2 H, H₂C(6));

^{*} The ¹H NMR spectrum of the melt is virtually identical with that of iminium salt 5a.^{2b}

5.77 (dddd, 1 H, HC(5), J = 6.9 Hz, J = 6.9 Hz, J = 10.1 Hz, J = 16.8 Hz) (cf. Ref. 6).

 (\pm) -N-(6-Bromomethyltetrahydropyran-2-ylidene)-N,Ndimethylammonium bromide (11) and (\pm) -N,N-dimethyl-5,6-dibromohexanamide (12). A solution of Br₂ (1.39 g, 8.7 mmol) in CHCl₃ (25 mL) was added at 0 °C (Ar) for 1 h to a stirred solution of amide 9 (1.23 g, 8.7 mmol) in CHCl₃ (25 mL). The reaction mixture was kept at this temperature for 20 min and concentrated in vacuo. The residue was triturated with Et2O (4×10 mL) until a homogeneous powdery product was formed, while decanting the ethereal solution. The product was crystallized from MeCN-Et₂O to give light yellow salt 11 (2.02 g, 77%), m.p. 85–89 °C (in a sealed capillary). Found (%): C, 31.31; H, 5.05; Br, 52.81; N, 4.70. C₈H₁₅Br₂NO. Calculated (%): C, 31.92; H, 5.02; Br, 53.09; N, 4.65. IR (CHCl₃, v/cm⁻¹): 656, 824, 924, 960, 1032, 1080, 1242, 1304, 1336, 1400, 1416, 1424, 1432, 1460, 1656, 2448, 2752, 2936, 3368. MS, *m/z* (*I*_{rel} (%); scan range from m/z 60 to m/z 500): 303.9 (20), 302.0 (30), 299.9 (15), 223.1 (10), 222.1 (100), 221.1 (10), 220.1 (90), 140.0 (15). MS/MS (m/z 302; the activation energy was 50% of the relative maximum collision energy): 222.0 (25), 221.0 (5), 220.0 (85), 219.3 (5), 141.0 (10), 140.1 (100), 138.2.9 (5). MS/MS (m/z 221); the activation energy was 30% of the relative maximum collision energy): 222.1 (15), 220.1 (20), 140.1 (100). ¹H NMR (200.13 MHz), δ : 1.82–2.21 (m, 4 H, H₂C(4), H₂C(5)); 2.94 (m, 2 H, H₂C(3)); 3.29 and 3.41 (both s, 3 H each, 2 Me); 3.69 (m, 2 H, H₂CBr); 5.06 (m, 1 H, HC(6)).

The combined ethereal supernatants were concentrated in vacuo and the residue was chromatographed on SiO₂ with light petroleum–MeOBu^t (1:3) as an eluent. The yield of dibromo amide 12 was 0.60 g (23%), colorless oil, $R_{\rm f}$ 0.32 (light petroleum-MeOBu^t, 1:4). Found (%): C, 31.70; H, 5.10; Br, 52.99; N, 4.95. C₈H₁₅Br₂NO. Calculated (%): C, 31.92; H, 5.02; Br, 53.09; N, 4.65. IR (thin film, v/cm⁻¹): 568, 612, 648, 752, 804, 872, 936, 1056, 1148, 1232, 1264, 1336, 1400, 1480, 1496, 1552, 1644, 1692, 1728, 2936, 3176. MS, *m/z* (*I*_{rel} (%)): $300 [M - 1]^+$ (2), 223 (11), 222 (74), 221 (5), 220 (75), 175 (5), 164 (2), 149 (19), 147 (18), 141 (26), 140 (89), 133 (4), 121 (13), 114 (24), 107 (8), 100 (21), 98 (20), 94 (19), 86 (69), 73 (22), 72 (100), 69 (28), 67 (47), 55 (73). ¹H NMR (200.13 MHz), δ: 1.65-2.41 (m, 6 H, 3 H₂C); 2.91 and 2.98 (both s, 3 H each, 2 Me); 3.62 (dd, 1 H, HC(6), J = 9.4 Hz, J = 10.3 Hz); 3.82 (dd, 1 H, H'C(6), J = 4.5 Hz, J = 10.3 Hz); 4.16 (dddd, 1 H, HC(5), J = 3.4 Hz, J = 4.5 Hz, J = 8.2 Hz, J = 9.3 Hz). ¹³C NMR (50.03 MHz), 8: 22.4, 32.3, 35.7 and 36.3 (4 CH₂); 35.4 and 37.2 (2 Me): 52.6 (HCBr): 172.1 (C=O).

(±)-6-Bromomethyltetrahydropyran-2-one (14). A solution of salt 11 (0.9 g, 3 mmol) and NaOAc \cdot 3H₂O (0.45 g, 3.3 mmol) in a mixture of MeCN (8 mL) and water (0.7 mL) was stirred at 20 °C for 5 h and concentrated *in vacuo*. The product was extracted from the residue with MeOBu^t. The extract was washed with water and brine, dried with Na₂SO₄, and concentrated *in vacuo*. The residue was chromatographed on SiO₂ with light petroleum—MeOBu^t (1 : 3) as an eluent. The yield of lactone 14 was 0.49 g (85%), colorless oil, R_f 0.43 (light petroleum—MeOBu^t, 1 : 4). ¹H NMR (200.13 MHz), δ : 1.90 (m, 4 H, 2 H₂C); 2.53 (m, 2 H, H₂C); 3.58 (dd, 1 H, HCBr, J = 4.9 Hz, J = 9.8 Hz); 3.58 (dd, 1 H, HCGh, J = 3.5 Hz, J = 4.7 Hz, J = 5.8 Hz, J = 10.3 Hz) (*cf.* Ref. 7).

(±)-*N*,*N*-**Diisopropyl-2-phenylsulfonylhex-5-enamide** (15). A ~55% suspension (142 mg) of NaH (~3.3 mmol) in mineral oil was added in portions at 10 °C (Ar) for 5 min to a stirred solution of N,N-diisopropyl-2-phenylsulfonylacetamide (16) (849 mg, 3.0 mmol) in DMF (4 mL). After 30 min, 4-bromobutene (446 mg, 3.3 mmol) was added. The reaction mixture was warmed to 20 °C, kept at this temperature for 15 h, and decomposed with water (15 mL). The organic material was extracted with Bu^tOMe. The organic layer was separated, washed with water and brine, dried with Na₂SO₄, and concentrated in vacuo. The residue was chromatographed on SiO₂. Gradient elution with light petroleum-Bu^tOMe from 2:1 to 1:1 gave amide **15** (0.8 g, 80%) as colorless crystals, m.p. 66-68 °C (from light petroleum). Found (%): C, 64.43; H, 7.97; N, 4.20; S, 9.53. C₁₈H₂₇NO₃S. Calculated (%): C, 64.06; H, 8.06; N, 4.15; S, 9.50. IR (KBr, v/cm⁻¹): 528, 568, 688, 712, 760, 848, 920, 1040, 1080, 1136, 1184, 1208, 1300, 1368, 1448, 1480, 1584, 1640, 2960-3032. MS, m/z (I_{rel} (%)): 337 [M]⁺ (4), 322 (9), 280 (2), 273 (3), 254 (2), 241 (2), 232 (17), 230 (8), 219 (2), 213 (2), 197 (16), 196 (69), 169 (5), 154 (17), 144 (44), 143 (66), 142 (70), 141 (34), 128 (15), 125 (46), 118 (12), 111 (21), 100 (54), 95 (58), 85 (100), 76 (50), 69 (74), 55 (55). ¹H NMR (200.13 MHz), δ: 1.17, 1.33 and 1.42 (all d, 3 H each, 3 Me, J = 6.8 Hz); 1.42 (d, 3 H, Me, J = 6.5 Hz); 1.83–2.16 (m, 4 H, 2 CH₂); 3.46 (quint, 1 H, <u>HC(Me)</u>₂, J = 6.8 Hz); 4.25–4.40 (m, 2 H, <u>HC(Me)</u>₂, HCS); 4.98 and 5.03 (both m, 1 H each, H₂C=); 5.70 (m, 1 H, HC=); 7.47–7.85 (m, 5 H, H_{arom}).

(3R*,6S*)- and (3R*,6R*)-N-(6-Bromomethyl-3-phenylsulfonyltetrahydropyran-2-ylidene)-N,N-diisopropylammonium bromides (17a,b) and N,N-diisopropyl-5,6-dibromo-2-phenylsulfonylhexanamides (18). A solution of Br₂ (0.48 g, 3.0 mmol) in CHCl₃ (60 mL) was added at $-10 \degree$ C (Ar) for 30 min to a stirred solution of amide 15 (1.01 g, 3.0 mmol) in CHCl₃ (50 mL). The reaction mixture was kept at this temperature for 30 min and concentrated in vacuo at 20 °C. The organic material was extracted from the residue (1.49 g) with Et₂O (3×15 mL) and dried in vacuo (2 Torr) to give a ~1.7:1 mixture of isomers 17a/17b (0.9 g, 60%) (¹H NMR) as a yellow powder. Isomer 17a was isolated by extraction with chloroform followed by precipitation with Et₂O (20 \rightarrow -20 °C). The purity of compound 17a was ~90% (¹H NMR). Crystallization of this product and the chloroform-insoluble residue containing the minor component gave analytically pure isomers 17a and 17b.

Bromide 17a: colorless crystals, m.p. 145–151 °C (decomp.). Found (%): C, 43.73; H, 5.29; Br, 32.35; N, 2.75; S, 6.49. C₁₈H₂₇Br₂NO₃S. Calculated (%): C, 43.47; H, 5.47; Br, 32.14; N. 2.82; S. 6.45. IR (KBr. v/cm⁻¹): 648, 688, 720, 760, 800, 856. 896, 940, 1040, 1068, 1088, 1104, 1120, 1152, 1224, 1288, 1296, 1312, 1328, 1340, 1376, 1392, 1412, 1448, 1520, 1568, 1616, 2936–3800. MS, m/z (I_{rel} (%); scan range from m/z 100 to *m*/*z* 510): 498.9 (10), 497.9 (50), 495.9 (100), 495.1 (20), 493.9 (50), 456.0 (15), 454.0 (30), 452.0 (15), 418.2 (40), 416.0 (35), 374.2 (5), 313.1 (15), 276.3 (25), 274.0 (20); MS/MS (*m*/*z* 496; the activation energy was 30% of the relative maximum collision energy): 455.8 (55), 453.8 (100), 451.8 (50), 373.9 (5), 355.9 (5), 353.9 (15), 314.8 (10), 312.8 (20), 290.0 (15), 276.0 (35), 274.0 (40). ¹H NMR (600.13 MHz, CD₃CN), δ: 1.39 and 1.48 (both d, 3 H each, 2 Me, J = 6.5 Hz); 1.53 and 1.58 (both d, 3 H each, 2 Me, J = 6.8 Hz); 1.87 (dddd, 1 H, H_{ax}C(5), J = 8.0 Hz, J = 10.4 Hz, J = 11.25 Hz, J = 14.4 Hz); 2.26 (dddd, 1 H, $H_{eq}C(5), J = 2.5 Hz, J = 3.0 Hz, J = 10.3 Hz, J = 14.4 Hz); 2.29$ (ddd, 1 H, $H_{ax}C(4)$, J = 2.5 Hz, J = 9.6 Hz, J = 11.3 Hz, J = 15.2 Hz; 2.40 (dddd, 1 H, H_{eq}C(4), J = 2.4 Hz, J = 8.0 Hz,

 $J = 10.3 \text{ Hz}, J = 15.2 \text{ Hz}); 3.70 \text{ (dd, 1 H, HCBr, } J = 7.2 \text{ Hz}, J = 12.2 \text{ Hz}); 3.85 \text{ (dd, 1 H, H'CBr, } J = 3.0 \text{ Hz}, J = 12.2 \text{ Hz}); 4.22 \text{ (sept, 1 H, HCN, } J = 6.8 \text{ Hz}); 4.61 \text{ (sept, 1 H, HC'N, } J = 6.5 \text{ Hz}); 5.10 \text{ (dddd, 1 H, HC(6), } J = 3.0 \text{ Hz}, J = 3.0 \text{ Hz}, J = 7.2 \text{ Hz}, J = 11.3 \text{ Hz}); 5.36 \text{ (dd, 1 H, HC(3), } J = 2.4 \text{ Hz}, J = 9.6 \text{ Hz}); 7.51 \text{ (t, 1 H, } J = 7.5 \text{ Hz}); 7.78 \text{ (dd, 2 H, HC_{arom}, } J = 7.5 \text{ Hz}, J = 7.8 \text{ Hz}); 8.04 \text{ (d, 1 H, HC_{arom}, } J = 7.8 \text{ Hz}).$ ¹³C NMR (150.03 MHz, CD₃CN), &: 19.6, 20.3 20.2, 20.8 (4 Me); 20.9 (C(4)), 25.0 (C(5)), 33.3 (C-Br); 54.7 (HCN) 58.6 (HC'N); 60.0 (HCS); 86.3 (C(6)); 130.5, 131.4, 132.1, 137.2 (C-Ar); 166.3 (C=N).

Bromide 17b: light yellow crystals, m.p. 95-107 °C (decomp.). Found (%): C, 43.69; H, 5.13; Br, 32.51; N, 2.75; S, 6.55. C₁₈H₂₇Br₂NO₃S. Calculated (%): C, 43.47; H, 5.47; Br, 32.14; N, 2.82; S, 6.45. IR (KBr, v/cm⁻¹): 456, 512, 584, 648, 696, 720, 768, 792, 856, 896, 952, 1048, 1080, 1104, 1128, 1152, 1256, 1284, 1300, 1312, 1380, 1400, 1420, 1448, 1544, 1612, 2864–3800. MS, m/z (I_{rel} (%); scan range from m/z 100 to *m*/*z* 2000): 498.1 (15), 496.1 (30), 494.1 (20), 454.1 (10), 419.3 (20), 418.2 (100), 417.0 (20), 416.2 (90), 376.2 (15), 336.3 (20), 313.1(10), 277.2(10), 276.0(20); MS/MS (m/z 496; the activation energy was 30% of the relative maximum collision energy): 377.6 (5), 371.9 (10), 356.0 (15), 353.9 (35), 352.0 (15), 314.9 (15), 312.8 (40), 289.9 (25), 276.0 (90), 275.0 (20), 274.0 (100), 250.0 (15), 232.1 (10), 223.7 (5), 178.9 (5), 142.9 (5); MS/MS (m/z 418); the activation energy was 30% of the relative maximum collision energy): 419.1 (5), 417.9 (15), 416.0 (10), 377.9 (5), 376.9 (15), 375.9 (95), 373.9 (100), 333.9 (5), 295.0 (5), 294.0 (25), 292.0 (35), 291.0 (30), 276.9 (70), 275.9 (40), 274.9 (70), 274.2 (40), 249.8 (8), 234.0 (45), 232.0 (45), 197.1 (5), 196.1 (40), 152.0 (5). ¹H NMR (600.13 MHz, CDCl₃), δ: 1.57 and 1.58 (both d, 3 H each, 2 Me, J = 6.5 Hz); 1.75 and 1.77 (both d, 3 H each, 2 Me, J = 6.8 Hz); 2.10–2.20 (m, 3 H, HC(4), H₂C(5)); 2.70–2.80 (m, 1 H, H'C(4)); 3.57 (dd, 1 H, HCBr, J = 7.3 Hz, J = 12.1 Hz); 3.82 (td, 1 H, H'CBr, J = 2.5 Hz, J = 12.1 Hz); 4.15 (m, 1 H, HCN); 5.2 (m, 1 H, HC'N); 5.3 (m, 1 H, HC(6), J = 2.5 Hz, J = 12.0 Hz); 6.9 (dd, 1 H, HC(3), J = 5.0 Hz, J = 7.0 Hz); 7.7 (t, 1 H, HC_{arom}, J = 7.7 Hz); 7.8 (t, 1 H, HC_{arom}, J = 7.5 Hz); 8.1 (d, 1 H, HC_{arom}, J = 7.9 Hz). ¹³C NMR (150.03 MHz, CDCl₃), δ: 19.8, 20.0, 20.1 and 21.5 (4 Me); 21.8 (C(4)), 26.0 (C(5)), 35.8 (C-Br); 53.4 (HCN) 58.2 (HCN); 59.3 (HCS); 84.2 (C(6)); 128.6 (C-Ar); 129.8(C-Ar); 134.2(C-Ar); 136.1(C-Ar); 166.9 (C=N).

Concentration of the above ethereal supernatant in vacuo gave a mixture of diastereomers 18 (0.59 g, 40%) as colorless crystals, m.p. 108-110 °C (light petroleum-MeOBu^t). Found (%): C, 43.67; H, 5.52; Br, 31.77; N, 2.81; S, 6.38. C₁₈H₂₇Br₂NO₃S. Calculated (%): C, 43.47; H, 5.47; Br, 32.14; N, 2.82; S, 6.45. IR (KBr, v/cm⁻¹): 480, 536, 568, 688, 720, 756, 800, 824, 872, 920, 1044, 1088, 1132, 1212, 1272, 1280, 1300, 1336, 1368, 1448, 1512, 1644, 2968–3800. MS, *m/z* (*I*_{rel} (%)): 497 [M]⁺ (2), 484 (7), 483 (5), 482 (18), 481 (11), 454 (2), 440 (5), 433 (11), 418 (22), 415 (12), 390 (4), 377 (5), 376 (26), 374 (19), 358 (67), 356 (89), 354 (44), 338 (9), 323 (13), 316 (14), 294 (5), 276 (12), 274 (16), 254 (6), 241 (13), 234 (15), 232 (39), 197 (37), 196 (75), 185 (20), 175 (23), 167 (18), 154 (23), 153 (61), 151 (25), 143 (89), 142 (91), 141 (62), 128 (54), 125 (62), 119 (58), 110 (46), 100 (82), 94 (74), 85 (100), 76 (75), 70 (60), 67 (75), 57 (61). ¹H NMR (600.13 MHz, CDCl₃), δ: 1.20 and 1.41 (both d, 3 H each, 2 Me, J = 6.8 Hz); 1.29 and 1.30 (both d, 3 H each, 2 Me, J = 6.4 Hz); 1.41 (d, 3 H, Me, J = 6.7 Hz); 1.56–2.41 (m, 4 H, 2 CH₂); 3.50 (m, 2 H, <u>H</u>C(Me)₂, HC(6)); 3.81 (m, 1 H, H^C(6)); 4.04 (m, 1 H, HC(5)); 4.33 (m, 2 H, <u>H</u>^C(Me)₂, <u>H</u>CS); 7.51–7.85 (m, 5 H, H_{arom}). ¹³C NMR (50.03 MHz, CDCl₃), 8: 20.0, 20.1, 20.3, and 21.2 (4 Me); 26.1, 26.9, 32.8, 33.4, 35.5, and 35.9 (3 CH₂); 46.9, 50.0, 50.5, and 51.4 (3 CH); 65.9, 66.4 (HCS); 172.1 (C=O).

References

- (a) M. V. Zlokazov, A. V. Lozanova, V. V. Veselovsky, *Mendeleev Commun.*, 2003, 242; (b) M. V. Zlokazov, A. V. Lozanova, V. V. Veselovsky, *Izv. Akad. Nauk, Ser. Khim.*, 2004, 521 [*Russ. Chem. Bull., Int. Ed.*, 2004, **53**, 547].
- (a) A. V. Lozanova, T. M. Ugurchieva, M. V. Zlokazov, A. V. Stepanov, V. V. Veselovsky, *Mendeleev Commun.*, 2006, 15;
 (b) A. V. Lozanova, T. M. Ugurchieva, V. V. Veselovsky, *Izv. Akad. Nauk, Ser. Khim.*, 2007, 124 [*Russ. Chem. Bull.*, *Int. Ed.*, 2007, 56, 130]; (c) T. M. Ugurchieva, A. V. Lozanova, M. V. Zlokazov, V. V. Veselovsky, *Izv. Akad. Nauk, Ser. Khim.*, 2007, 1485 [*Russ. Chem. Bull.*, *Int. Ed.*, 2007, 56, 1544];
 (d) T. M. Ugurchieva, A. V. Lozanova, M. V. Zlokazov, V. V. Veselovsky, *Izv. Akad. Nauk, Ser. Khim.*, 2008, 644 [*Russ. Chem. Bull.*, *Int. Ed.*, 2008, 57, 657].
- 3. M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, J. A. Montgomery Jr., T. Vreven, K. N. Kudin, J. C. Burant, J. M. Millam, S. S. Iyengar, J. Tomasi, V. Barone, B. Mennucci, M. Cossi, G. Scalmani, N. Rega, G. A. Petersson, H. Nakatsuji, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, M. Klene, X. Li, J. E. Knox, H. P. Hratchian, J. B. Cross, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, P. Y. Ayala, K. Morokuma, G. A. Voth, P. Salvador, J. J. Dannenberg, V. G. Zakrzewski, S. Dapprich, A. D. Daniels, M. C. Strain, O. Farkas, D. K. Malick, A. D. Rabuck, K. Raghavachari, J. B. Foresman, J. V. Ortiz, Q. Cui, A. G. Baboul, S. Clifford, J. Cioslowski, B. B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R. L. Martin, D. J. Fox, T. Keith, M. A. Al-Laham, C. Y. Peng, A. Nanayakkara, M. Challacombe, P. M. W. Gill, B. Johnson, W. Chen, M. W. Wong, C. Gonzalez, J. A. Pople, Gaussian 03, Revision B.02, Gaussian, Inc.; Pittsburgh PA: 2003.
- 4. E. K. Starostin, A. V. Ignatenko, M. A. Lapitskaya, K. K. Pivnitskii, G. I. Nikishin, *Izv. Akad. Nauk, Ser. Khim.*, 2001, 797 [*Russ. Chem. Bull., Int. Ed.*, 2001, **50**, 833].
- 5. E. F. Witucki, G. L. Rowley, M. Warner, M. B. Frankel, *J. Org. Chem.*, 1972, **37**, 192.
- 6. J. T. Gupton, D. Baran, R. Bennett, G. R. Hertel, *Synth. Commun.*, 1984, **14**, 1001.
- 7. D. Ch. Braddock, G. Cansell, S. A. Hermitage, Chem. Commun., 2006, 2483.

Received October 15, 2009; in revised form March 1, 2010